Trial Profile
Evaluate Immunogenicity, Safety and Reactogenicity of a Booster Dose of Hib-MenC Conjugate Vaccine When Given to Healthy Subjects Aged 13-14 Mths Who Were Primed With 3 Doses of Hib-MenC vs a Booster Dose of Infanrix Hexa Given to Subjects Primed With 3 Doses of Infanrix Hexa and Meningitec
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Acronyms Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097
- Sponsors GlaxoSmithKline
- 17 Apr 2014 New trial record